Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Debt (2022 - 2024)

Summit Therapeutics filings provide 3 years of Non-Current Debt readings, the most recent being $100.0 million for Q1 2024.

  • Quarterly Non-Current Debt changed 0.0% to $100.0 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $100.0 million through Mar 2024, changed 0.0% year-over-year, with the annual reading at $100.0 million for FY2023, 79.78% down from the prior year.
  • Non-Current Debt hit $100.0 million in Q1 2024 for Summit Therapeutics, roughly flat from $100.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $494.5 million in Q4 2022 and bottomed at $25.1 million in Q1 2022.
  • Average Non-Current Debt over 3 years is $135.0 million, with a median of $100.0 million recorded in 2023.
  • Peak annual rise in Non-Current Debt hit 299.12% in 2023, while the deepest fall reached 79.78% in 2023.
  • Summit Therapeutics' Non-Current Debt stood at $494.5 million in 2022, then tumbled by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Debt are $100.0 million (Q1 2024), $100.0 million (Q4 2023), and $100.0 million (Q2 2023).